Inhibrx reports Q2 2026 results, sets Q3 PFS readout for INBRX-106

Inhibrx Biosciences reported financial results for the second quarter of 2026 on August 13, 2026. The biopharmaceutical company has two programs in ongoing clinical trials.¹

For INBRX-106, the company plans to announce progression-free survival data from the randomized Phase 2 trial in head and neck squamous cell carcinoma in combination with pembrolizumab in the third quarter of 2026.¹

For ozekibart (INBRX-109), during the second quarter of 2026 Inhibrx initiated two additional Phase 1 cohorts in colorectal cancer: a second line study combining ozekibart with Folfiri and Avastin, and a third/fourth line study combining ozekibart with Lonsurf and Avastin.¹ Interim results from these cohorts are expected in the first quarter of 2027.¹ On the regulatory side, in June 2026 the FDA accepted for filing the company's biologics license application for ozekibart in conventional chondrosarcoma and assigned a PDUFA goal date of April 14, 2027.¹ The company plans to meet with the FDA in the fourth quarter of 2026 to discuss a first-line registrational trial in colorectal cancer and a potential accelerated pathway for ozekibart in fourth-line colorectal cancer.¹

On financing, in July 2026 the company entered into a second amendment to its Loan and Security Agreement with Oxford Finance LLC, providing for up to $325.0 million in additional gross proceeds, with $100.0 million funded at signing and up to $225.0 million more available in increments of $50.0 million or more at Oxford's discretion.¹

As of June 30, 2026, the company had cash and cash equivalents of $133.3 million, which rose to $219.5 million as of August 6, 2026,¹ after the July 15, 2026 Oxford amendment brought in $100.0 million in gross proceeds.¹